BioDelivery Sciences International is a drug manufacturers - specialty & generic business based in the US. BioDelivery Sciences International shares (BDSI) are listed on the NASDAQ and all prices are listed in US Dollars. BioDelivery Sciences International employs 200 staff and has a trailing 12-month revenue of around $166.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.59 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $4.96 |
| 200-day moving average | $3.88 |
| Wall St. target price | $5.38 |
| PE ratio | 6.8171 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.82 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.59 from 2022-03-31
| 1 week (2024-07-15) | N/A |
|---|---|
| 1 month (2024-06-22) | N/A |
| 3 months (2024-04-22) | N/A |
| 6 months (2024-01-22) | N/A |
| 1 year (2023-07-22) | N/A |
|---|---|
| 2 years (2022-07-22) | N/A |
| 3 years (2021-07-26) | 54.42% |
| 5 years (2019-07-26) | 50.27% |
Valuing BioDelivery Sciences International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioDelivery Sciences International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioDelivery Sciences International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, BioDelivery Sciences International shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
BioDelivery Sciences International's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.95. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioDelivery Sciences International's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioDelivery Sciences International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $44.5 million.
The EBITDA is a measure of a BioDelivery Sciences International's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $166.7 million |
|---|---|
| Operating margin TTM | 22.27% |
| Gross profit TTM | $143.3 million |
| Return on assets TTM | 8.22% |
| Return on equity TTM | 57.33% |
| Profit margin | 50.91% |
| Book value | $1.90 |
| Market Capitalization | $577.1 million |
TTM: trailing 12 months
We're not expecting BioDelivery Sciences International to pay a dividend over the next 12 months.
Over the last 12 months, BioDelivery Sciences International's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioDelivery Sciences International's is 0.5551. This would suggest that BioDelivery Sciences International's shares are less volatile than average (for this exchange).
BioDelivery Sciences International, Inc. , a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.